Noctrix Health Enrolls First Patient in Wearable RLS Therapy Clinical Trial
The RESTFUL Study is a two-phase, randomized, double-blind, sham-controlled clinical trial to evaluate the company’s wearable NTX100 Neuromodulation System in patients with moderate-severe primary RLS.
Read More